Saturday 17 October 2026
Export CLYM’s income statement to Excel — free account
Climb Bio, Inc.
CLYM Healthcare Biotechnology
In the quarter to June 2026, EPS fell 38.5% and free cash flow grew 3.73%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.82
1.09
−9.99%
Follow CLYM
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
15.16 | 31.41 | 38.92 | 22.04 | 24.58 | 7.18 | 27.18 | — |
Net Debt/EBITDA |
1.44 | 1.82 | 2.51 | 2.73 | 3.87 | 0.98 | 2.85 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.91 | 0.21 | 0.59 | 0.83 | 0.69 | 0.61 | 0.68 | — |
Capex/Depreciation |
0.09 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| (32.15%) | (46.26%) | (29.72%) | (30.58%) | (73.17%) | 150.29% | 48.39% | — | |
| (31.10%) | (45.11%) | (28.61%) | (29.36%) | (52.59%) | (99.74%) | (69.09%) | — | |
ROIC |
(71.43%) | (84.09%) | (3,142.56%) | (547.86%) | (72.57%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(60.36%) | (49.22%) | (32.69%) | (35.14%) | (36.58%) | (121.22%) | (36.05%) | — |
Average Days of Receivables |
— | — | — | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.80) | (0.32) | (0.76) | (1.42) | (2.94) | (6.44) | (0.19) | — |
Cash per Share |
1.49 | 3.13 | 3.96 | 4.70 | 11.13 | 9.36 | 0.81 | — |
Shareholders Equity per Share |
2.37 | 4.40 | 3.99 | 4.89 | 13.64 | (11.42) | 0.78 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.37 | 4.40 | 3.99 | 4.89 | 13.64 | (11.42) | 0.78 | — |
Free Cash Flow |
(54.54) | (15.56) | (20.60) | (37.37) | (36.07) | (14.10) | (5.01) | — |
Working Capital |
98.87 | 149.94 | 107.42 | 128.30 | 142.22 | 18.94 | 20.50 | — |
Capital Expenditures |
(0.19) | — | — | — | — | — | — | — |
Net Current Asset Value |
98.58 | 149.57 | 107.39 | 128.12 | 142.21 | (27.62) | 20.50 | — |
| Other line items | ||||||||
Quick Ratio |
14.47 | 30.61 | 37.70 | 20.27 | 22.63 | 6.69 | 27.10 | — |
Depreciation/Fixed assets |
(7.56) | (3.80) | 0.00 | (0.38) | 0.00 | — | — | — |
Cash ROIC |
(20.85%) | (4.29%) | (9.61%) | (14.81%) | (11.88%) | 313.57% | (11.97%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.80) | (0.32) | (0.76) | (1.42) | (2.94) | (6.44) | (0.19) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
1.49 | 0.39 | 0.41 | 1.08 | 1.35 | 1.35 | — | — |
Average Assets |
192.47 | 163.83 | 122.73 | 154.12 | 98.94 | 23.01 | 10.70 | — |
Average Common Equity |
186.18 | 159.74 | 118.16 | 147.96 | 71.11 | (15.27) | (15.27) | — |
Capex to Sales |
0.00 | — | — | — | — | — | — | — |
Columns are period end dates